|Articles|December 22, 2021

Phase 1/2 Trial Results Underscore Teclistamab’s Efficacy in RRMM

Updated results of the MajesTEC -1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate of 62% among heavily pretreated patients with multiple myeloma.

Updated results of the MajesTEC-1 phase 1/2 study on teclistamab showed the treatment resulted in an overall response rate (ORR) of 62% (95% CI, 53.7%-69.8%) among patients with relapsed/refractory multiple myeloma (RRMM), suggesting treatment responses were durable and deepened over time.

Additional findings were presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition, which took place December 11 -14 in Atlanta, Georgia.

Teclistamab is a T-cell redirecting, bispecific IgG4 antibody that targets the B-cell maturation antigen (BCMA) and CD3 receptors to induce T-cell–mediated cytotoxicity of BCMA-expressing myeloma cells, researchers explained.

Internal server error